Aerie Pharmaceuticals Inc (AERI) : Simplex Trading scooped up 19,477 additional shares in Aerie Pharmaceuticals Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Oct 7, 2016. The investment management firm now holds a total of 19,988 shares of Aerie Pharmaceuticals Inc which is valued at $809,314.Aerie Pharmaceuticals Inc makes up approximately 0.11% of Simplex Trading’s portfolio.
Other Hedge Funds, Including , First Mercantile Trust Co added AERI to its portfolio by purchasing 4,271 company shares during the most recent quarter which is valued at $172,933. Aerie Pharmaceuticals Inc makes up approx 0.02% of First Mercantile Trust Co’s portfolio.Bnp Paribas Arbitrage Sa boosted its stake in AERI in the latest quarter, The investment management firm added 723 additional shares and now holds a total of 1,660 shares of Aerie Pharmaceuticals Inc which is valued at $65,172.
Aerie Pharmaceuticals Inc opened for trading at $40.26 and hit $40.66 on the upside on Friday, eventually ending the session at $40.49, with a gain of 0.20% or 0.08 points. The heightened volatility saw the trading volume jump to 6,55,304 shares. Company has a market cap of $1,129 M.
Many Wall Street Analysts have commented on Aerie Pharmaceuticals Inc. H.C. Wainwright Initiated Aerie Pharmaceuticals Inc on Sep 20, 2016 to “Buy”, Price Target of the shares are set at $66.Company shares were Reiterated by RBC Capital Mkts on Sep 15, 2016 to “Outperform”, Firm has raised the Price Target to $ 55 from a previous price target of $51 .Company shares were Reiterated by Needham on Sep 15, 2016 to “Buy”, Firm has raised the Price Target to $ 52 from a previous price target of $45 .
Aerie Pharmaceuticals Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s primary product candidates triple-action Rhopressa and quadruple-action Roclatan are once-daily eye drops. The Company’s product candidate once-daily quadruple-action Roclatan is a single drop fixed-dose combination of Rhopressa and latanoprost. Rhopressa inhibits Rho Kinase (ROCK) and the norepinephrine transporter (NET) which are both biochemical targets for lowering intraocular pressure (IOP). The Company’s Rhopressa product candidate was in Phase III stage of development. The Company has completed the Roclatan Phase IIb clinical trial. The Company is also in the preclinical development stage with AR-13533 its second-generation ROCK/NET inhibitor.